- Home
- ACIU vs DCTH Comparison
ACIU vs DCTH Comparison
Compare ACIU & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- DCTH
- Stock Information
- Founded
- ACIU 2003
- DCTH 1988
- Country
- ACIU Switzerland
- DCTH United States
- Employees
- ACIU N/A
- DCTH N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- ACIU Health Care
- DCTH Health Care
- Exchange
- ACIU Nasdaq
- DCTH Nasdaq
- Market Cap
- ACIU 213.3M
- DCTH 388.3M
- IPO Year
- ACIU 2016
- DCTH N/A
- Fundamental
- Price
- ACIU $2.48
- DCTH $10.67
- Analyst Decision
- ACIU Strong Buy
- DCTH Strong Buy
- Analyst Count
- ACIU 2
- DCTH 4
- Target Price
- ACIU $10.00
- DCTH $24.50
- AVG Volume (30 Days)
- ACIU 132.0K
- DCTH 485.5K
- Earning Date
- ACIU 11-04-2025
- DCTH 11-07-2025
- Dividend Yield
- ACIU N/A
- DCTH N/A
- EPS Growth
- ACIU N/A
- DCTH N/A
- EPS
- ACIU N/A
- DCTH 0.06
- Revenue
- ACIU $36,362,036.00
- DCTH $70,240,000.00
- Revenue This Year
- ACIU N/A
- DCTH $159.22
- Revenue Next Year
- ACIU $1,022.98
- DCTH $41.22
- P/E Ratio
- ACIU N/A
- DCTH $193.75
- Revenue Growth
- ACIU 86.71
- DCTH 491.35
- 52 Week Low
- ACIU $1.43
- DCTH $8.08
- 52 Week High
- ACIU $3.98
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- ACIU 64.11
- DCTH 43.30
- Support Level
- ACIU $2.12
- DCTH $10.60
- Resistance Level
- ACIU $2.35
- DCTH $11.38
- Average True Range (ATR)
- ACIU 0.13
- DCTH 0.44
- MACD
- ACIU 0.04
- DCTH 0.01
- Stochastic Oscillator
- ACIU 95.74
- DCTH 5.26
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.